Terrance Mcguire Sells 119,805 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 119,805 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $0.42, for a total value of $50,318.10. Following the transaction, the director now directly owns 3,568,274 shares in the company, valued at $1,498,675.08. The trade was a 3.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Trading Up 4.0 %

Shares of NASDAQ:IVVD opened at $0.53 on Friday. Invivyd, Inc. has a 1-year low of $0.40 and a 1-year high of $5.20. The stock has a market capitalization of $63.44 million, a P/E ratio of -0.27 and a beta of 0.53. The business has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $0.99.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IVVD. State Street Corp lifted its holdings in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Marshall Wace LLP raised its position in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after acquiring an additional 474,301 shares in the last quarter. Duquesne Family Office LLC acquired a new position in Invivyd during the 2nd quarter worth approximately $629,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Invivyd in the second quarter valued at approximately $421,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IVVD shares. HC Wainwright decreased their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. Finally, Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.